What renal diseases are associated with polymyalgia rheumatica?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Renal Disease Associated with Polymyalgia Rheumatica

Polymyalgia rheumatica (PMR) is rarely associated with renal disease, but when it occurs, the most important manifestation is AA-type (secondary) amyloidosis, which can lead to nephrotic syndrome and end-stage renal failure. Other rare renal complications include glomerulonephritis and tubulointerstitial nephritis.

Primary Renal Manifestation: AA Amyloidosis

The most clinically significant renal complication of PMR is secondary (AA-type) amyloidosis, which develops from chronic inflammation 1, 2. This can progress rapidly—one case report documented development of nephrotic range proteinuria and deteriorating renal function within just 18 months of PMR symptom onset 1. The amyloid deposits are confirmed by immunohistochemical analysis showing AA-type protein 2.

Clinical Presentation of AA Amyloidosis in PMR:

  • Nephrotic syndrome (heavy proteinuria)
  • Progressive renal failure
  • Can advance to end-stage renal disease requiring dialysis 3
  • May occur despite aggressive treatment with steroids and other immunosuppressants 3

Other Rare Renal Manifestations

Glomerulonephritis

Diffuse endocapillary proliferative glomerulonephritis has been documented in PMR patients presenting with proteinuria and hematuria 4. This responds well to low-dose prednisolone (10 mg/day), with improvement in both urinary abnormalities and systemic symptoms 4.

Tubulointerstitial Nephritis

One case report documented acute tubulointerstitial nephritis in a PMR patient with concurrent subclinical Sjögren's syndrome 5. Gallium scintigraphy showed marked renal accumulation, and renal biopsy revealed lymphocytic infiltration. This responded to high-dose methylprednisolone 5.

Clinical Implications and Monitoring

The key clinical message is that renal involvement in PMR is extremely rare but carries serious prognostic implications when present 1. The most recent PMR guidelines 6 do not specifically address renal complications, as they focus on musculoskeletal manifestations and glucocorticoid management. However, the rarity of renal involvement should not lead to complacency.

Practical Monitoring Approach:

  • Check baseline renal function (creatinine, eGFR) and urinalysis at PMR diagnosis
  • Monitor for proteinuria during follow-up, particularly in patients with prolonged disease or inadequate inflammatory control
  • Consider renal biopsy if significant proteinuria (>0.3 g/day) or hematuria develops 4
  • Maintain vigilance in patients requiring prolonged glucocorticoid therapy, as persistent inflammation increases AA amyloidosis risk 1

Important Caveat:

The differential diagnosis must include vasculitis (particularly giant cell arteritis with renal involvement), as 5-10% of PMR patients develop GCA 6. Vasculitis can also cause renal disease and requires different management intensity.

Treatment Considerations

When renal disease is identified in PMR:

  • AA amyloidosis: Requires aggressive control of underlying inflammation to halt amyloid deposition; prognosis is often poor once established 3, 2
  • Glomerulonephritis: May respond to standard PMR glucocorticoid doses 4
  • Tubulointerstitial nephritis: May require higher-dose glucocorticoids initially 5

The presence of renal complications should prompt consideration of glucocorticoid-sparing agents (methotrexate or IL-6 receptor inhibitors) to achieve better inflammatory control while minimizing long-term glucocorticoid toxicity 6, 7.

Related Questions

In a patient with polymyalgia rheumatica, is the anemia of chronic disease typically normocytic or microcytic?
Can hematocrit be elevated in patients with polymyalgia rheumatica?
In an older adult being evaluated for polymyalgia rheumatica, can warm pitting edema of the legs be related to the disease?
Can celecoxib (Celebrex) be used for treatment of polymyalgia rheumatica?
In an 80‑year‑old patient with morning hand stiffness, right ankle pain and swelling, a normal uric acid level, and a positive rheumatoid factor, what is the most likely diagnosis and recommended initial treatment?
In individuals older than 65 years, is frequent daytime napping or prolonged nighttime sleep associated with an increased risk of dementia?
What is the efficacy and recommended regimen of Pylera (bismuth subcitrate potassium, tetracycline, metronidazole) for treating recurrent Helicobacter pylori infection, and what are its contraindications?
What comprehensive hormonal panel should I have ordered to evaluate my female sex hormones given that I feel on edge?
What are the five most prescribed antimalarial agents and the geographic regions where each is active?
Which antimalarial agents are most commonly prescribed in Canada for prophylaxis and treatment, and in which endemic regions do they remain effective?
As a healthcare provider evaluating patients traveling to Spain, what specific communicable diseases and assessments must I review to certify, per the International Health Regulations (2005), that they do not have any condition that could cause serious public‑health repercussions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.